TSD Life Sciences
Next-generation immuno-oncology therapeutics and clinical research services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | KRW10.0b | Series A | |
| Total Funding | 000k | ||
TSD Life Sciences is a biotechnology company founded in 2016, dedicated to developing treatments for cancer. The company's business model transitioned from a clinical consulting service to a research-focused biotech firm. The founder and CEO is Jewon Lee, who previously worked at LG Life Sciences and Hanwha before establishing TSD Life Sciences.
The company's primary focus is on immuno-oncology, leveraging two main platform technologies. One is an iPSC-derived NK (Natural Killer) cell therapy engineered to express IL-7 and CCL19. The second is a small molecule kinase inhibitor based on a proprietary scaffold, targeting metastatic castration-resistant prostate cancer (mCRPC). Its pipeline includes candidates like TSD101 for multiple myeloma, an antibody-drug conjugate (ADC) with a unique target, and TSD204 for AML and solid tumors. TSD Life Sciences also provides clinical research and outsourcing services, guiding organizations through regulatory strategy, compliance, and clinical trial processes to accelerate the delivery of new therapies. The company serves other biotech and pharmaceutical organizations, forming deep partnerships to support their development challenges.
TSD Life Sciences has secured funding from investors including Korea Investment Partners, IBK Capital, Boditech Med, and Cytogen. It engages in collaborations, such as a partnership with Standigm to use an AI platform for developing a small molecule anticancer drug, aiming to shorten development timelines.
Keywords: immuno-oncology, cancer therapeutics, iPSC-derived NK cell therapy, small molecule kinase inhibitor, antibody-drug conjugate, clinical research services, drug discovery, metastatic prostate cancer, multiple myeloma, solid tumors, blood cancer, biotech, biopharmaceutical, oncology R&D, clinical trial consulting, regulatory strategy, orphan drugs, AML treatment, cell therapy